l e t t e r s RNA interference (RNAi) has great potential to treat human disease [1] [2] [3] . However, in vivo delivery of short interfering RNAs (siRNAs), which are negatively charged double-stranded RNA macromolecules, remains a major hurdle [4] [5] [6] [7] [8] [9] . Current siRNA delivery has begun to move away from large lipid and synthetic nanoparticles to more defined molecular conjugates 9 . Here we address this issue by synthesis of short interfering ribonucleic neutrals (siRNNs) whose phosphate backbone contains neutral phosphotriester groups, allowing for delivery into cells. Once inside cells, siRNNs are converted by cytoplasmic thioesterases into native, charged phosphodiester-backbone siRNAs, which induce robust RNAi responses. siRNNs have favorable druglike properties, including high synthetic yields, serum stability and absence of innate immune responses. Unlike siRNAs, siRNNs avidly bind serum albumin to positively influence pharmacokinetic properties. Systemic delivery of siRNNs conjugated to a hepatocyte-specific targeting domain induced extended dose-dependent in vivo RNAi responses in mice. We believe that siRNNs represent a technology that will open new avenues for development of RNAi therapeutics.
Unlike small molecule inhibitors (<500 Da) that can passively diffuse across cellular membranes 10 , siRNAs are both too large (~14 kDa) and too charged (~40 charged phosphates) to enter cells on their own [4] [5] [6] [7] . Consequently, siRNA delivery remains the major technological problem for development of RNAi therapeutics [1] [2] [3] [4] [5] [6] [7] [8] [9] . Improvements in siRNA delivery have begun to move away from large lipid and synthetic nanoparticles (~10 8 Da) that are >1,000× larger than the siRNA drug to more definable molecular conjugates 9 . However, because efficient RNAi responses require TRBP enzymatic loading of negatively charged double-stranded A-form siRNAs into Argonaute2 (Ago2), the catalytic core of the RNAi machinery 11, 12 , the negatively charged phosphodiester siRNA backbone has remained recalcitrant to chemical manipulation and presents a significant unsolved problem for siRNA delivery. To address this problem, we synthesized siRNNs with neutralizing bioreversible phosphotriester groups that are intracellularly converted into a native charged phosphate backbone (Fig. 1a,b) .
Unlike the 5′ or 3′ end of an oligonucleotide, native negatively charged phosphodiester linkages cannot be modified after oligonucleotide synthesis without inadvertently alkylating the nucleobases 13, 14 . Therefore, we pursued a chemical approach that placed the bioreversible phosphotriester group on phosphoramidite building blocks used for RNN oligonucleotide synthesis. Several groups have previously developed single-stranded deoxyoligonucleotide charge neutralization approaches using irreversible and reversible phosphotriester groups [15] [16] [17] [18] [19] , but none of these approaches has been applied to double-stranded DNA or RNA molecules. After reviewing the literature, we focused our efforts on a thioester bond containing S-acyl-2-thioethyl (SATE) phosphotriester group that was originally developed in the early 1990s in Imbach's laboratory as a monophosphate nucleotide prodrug inhibitor of HIV and hepatitis B virus [20] [21] [22] . Extracellular esterases are unable to cleave thioester bonds; however, once inside cells, cytoplasmic thioesterases cleave the SATE thioester bond to initiate a rapid two-step conversion that unmasks the charged phosphate group 20 (Fig. 1b) . Unfortunately, expansion of SATE phosphotriesters to single-stranded DNA oligonucleotides in the late 1990s resulted in poor synthetic yields that made phenotypic biological analyses or synthesis of double-stranded RNA (or DNA) molecules impossible [23] [24] [25] . In our hands, synthesizing RNN oligonucleotides required addressing multiple chemical complexities, including dipole moment destabilization of the thioester bond, 2′ hydroxyl nucleophilic attack on the phosphotriester linkage, nucleobase protecting group stability, deprotection and high-performance liquid chromatography (HPLC) purification conditions that avoided phosphotriester cleavage or strand scission, and hydrophobicity. We exhaustively addressed these problems in an orthogonally compatible fashion that maintained high yields and used standard solid-phase oligonucleotide synthesis conditions (Supplementary Fig. 1a) .
To develop siRNNs, we synthesized a library of >40 phosphotriester groups on RNN phosphoramidite building blocks ( Supplementary  Fig. 1b ). To prevent a cis 2′ hydroxyl nucleophilic attack on efficient delivery of rNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications the phosphotriester linkage 26 , RNN phosphoramidites contain 2′ modifications (2′-F, pyrimidines; 2′-O-Me, purines) that are highly tolerated by the RNAi machinery and used on all therapeutic siRNAs in clinical trials 2, 3, 6, 8, 9 . To prevent base-mediated phosphotriester cleavage during nucleobase deprotection, RNN phosphoramidites contain phenoxyacetyl chloride protecting groups 27 on adenine and cytosine, and isopropyl-phenoxyacetyl chloride on guanosine that allowed for deprotection using extremely mild basic diisopropylamine (DIA) in methanol (Supplementary Fig. 2a) . Stabilization of the thioester bond to DIA/methanol required substituting electrondonating groups at the distal α-carbon position or lengthening the proximal ethyl linker to a butyl linker (Supplementary Fig. 1b) . RNN oligonucleotide synthesis results in high yields (93.0% yield; 99.6% coupling efficiency) that are comparable to RNA synthesis (85.7% yield; 99.2% coupling efficiency; Supplementary Fig. 2b,c) . After screening the RNN phosphoramidite library, we focused on three bioreversible phosphotriester groups, namely, tBu-SATE, hydroxyl O-SATE and a conjugatable aldehyde A-SATE, as well as a control irreversible phosphotriester dimethyl-butyl (DMB) group (Fig. 1c) .
Biophysical analyses by gel electrophoresis showed that increasing the number of phosphotriester groups resulted in a concomitant RNN charge neutralization, especially at 14 and 16 phosphotriester insertions ( Fig. 1d and Supplementary Fig. 2d ). Synthesis of doublestranded siRNNs with 18× tBu-SATE phosphotriesters resulted in a salt-mediated hydrophobic collapse, but substitution of 18× hydrophilic hydroxyl O-SATE phosphotriesters rescued solubility (Fig. 1c,e and Supplementary Fig. 2e ). Phosphotriester groups on RNN oligonucleotides were markedly stable in serum ( Fig. 1f and Supplementary Fig. 2f ). We believe that the generation of siRNNs with chemically reactive aldehyde A-SATE phosphotriester groups will be very useful as this allows for efficient conjugation to hydrazinecontaining delivery domain peptides 28, 29 and targeting domains at defined locations on siRNNs (Fig. 1c,g and Supplementary Fig. 2g ).
siRNAs contain a central major groove core that is bordered by phosphates #1 to #11 from both strands (Fig. 1a) . Passenger strand phosphate #1 (P#1) sterically opposes guide strand phosphate G#11 across the major groove. Likewise, P#2 opposes G#10, and so on. In contrast, phosphates #12 to #20 on the 3′ ends of both strands are not Fig. 2h ). PO 4 , phosphate; WT, wild type.
npg l e t t e r s opposed to other phosphates and have a greater solution accessibility, thus we term them 3′ open phosphates (Fig. 1a) . During oligonucleotide synthesis, oxidation of the chiral phosphorous randomly generates either an Sp (outward) or an Rp (inward) diastereomer of the phosphotriester group (Fig. 1h) Fig. 1i and Supplementary Fig. 2h ). However, moving a single phosphotriester from a 3′ open phosphate position into the major groove destabilized duplex formation (Fig. 1i) . Thus, phosphotriester placement has an impact on siRNN duplex formation.
To assay for intracellular conversion of phosphotriester siRNNs into charged phosphodiester siRNAs, we used 32 P to label the 5′ end of guide strand oligonucleotides containing wild-type phosphodiesters, six bioreversible tBu-SATE phosphotriesters or six control irreversible DMB phosphotriesters that were then duplexed to unlabeled wild-type passenger strands (Supplementary Fig. 3a ). The 32 P-labeled siRNNs were transfected into cells, then lysed, and Ago2-associated, 32 P-labeled guide strand oligonucleotides were co-immunoprecipitated with anti-Ago2 antibodies (Fig. 2a) . As expected, the positive control 32 P-labeled wild-type phosphodiester siRNA guide strand co-immunoprecipitated with Ago2 as a full-length guide strand. However, Ago2-associated 32 P-labeled tBu-SATE siRNN guide strand migrated as a quantitatively converted, native charged phosphodiester siRNA guide strand (Fig. 2a) . In contrast, we detected only background levels of control 32 P-labeled irreversible DMB guide strand associated with Ago2 that had not undergone conversion. To determine if in vivo conversion of siRNNs into siRNAs induced a characteristic Ago2 mRNA cleavage, we performed a 5′ rapid amplification of cDNA ends (RACE) analysis 4, 6 of GFP mRNA from cells transfected with bioreversible tBu-SATE phosphotriester GFP siRNN and positive control GFP siRNA (Supplementary Fig. 2e ). Both GFP siRNN and siRNA induced correct Ago2-dependent cleavage, whereas nontargeting control siRNA failed to cleave GFP mRNA (Fig. 2b) . Consistent with these observations, transfection of tBu-SATE and O-SATE phosphotriester GFP and luciferase siRNNs (Supplementary Fig. 2e ) induced robust dose-dependent RNAi responses, whereas control irreversible DMB siRNNs did not (Supplementary Fig. 3b-g) .
Recognition of exogenous RNAs by the innate immune system's Toll-like receptors remains problematic for development of RNAi therapeutics 30, 31 . Exposure of primary human peripheral blood mononuclear cells (PBMCs) to a highly stimulatory β-gal siRNA (2′ hydroxyl) sequence 32 npg l e t t e r s interferon-α and tumor necrosis factor-α ( Fig. 2c and Supplementary  Fig. 4a,b) . However, both a fully 2′-modified β-gal siRNA and a β-gal siRNN containing 14 phosphotriesters failed to stimulate an innate immune response, suggesting that siRNNs containing phosphotriesters are not recognized by the innate immune system (Fig. 2c) .
To determine the requirements for efficient intracellular phosphotriester conversion, we synthesized GFP siRNNs containing phosphotriester groups that were altered surrounding the thioester bond. Transfection of GFP siRNNs containing six tBu-SATE phosphotriesters on the guide strand with an ethyl linker between the phosphate oxygen and thioester bond, which uses a favored three-membered ring intermediate, efficiently converted to active siRNAs to induce GFP RNAi responses, whereas placement of six irreversible control DMB phosphotriesters did not ( Fig. 2d and Supplementary Fig. 4c) . GFP siRNNs containing phosphotriesters with a propyl linker (tBu-Sacyl-thiopropyl [tBu-SATP]), which uses a geometrically unfavored four-membered ring during conversion, showed poor induction of GFP RNAi. Addition of a butyl phosphotriester linker (tBu-S-acylthiobutyl [tBu-SATB]), which uses a favored five-membered ring intermediate, resulted in an intermediate RNAi response. However, reducing the distal electron donor from a tbutyl group to an isopropyl group (iPr-S-acyl-thiobutyl [iPr-SATB]) restored full GFP RNAi activity (Fig. 2d) . By contrast, the combination of a distal isopropyl group and a pentyl linker 33 (iPr-S-acyl-thioethoxyethyl [iPr-SATEE]), which uses a six-member ring intermediate, performed poorly, suggesting that the distance between the reactive sulfur and the phosphorus is critical for efficient conversion.
Like siRNAs (~14 kDa), siRNNs (~17 kDa) are too large to passively diffuse across the cell membrane 10 . Therefore, we selectively conjugated a TAT peptide delivery domain 28, 29 to siRNNs via conjugatable A-SATE phosphotriesters (Fig. 1c,g ). In contrast to the confined small chemical motifs placed distal to SATE groups on monophosphate nucleoside inhibitors [20] [21] [22] , we discovered that regardless of length, the entire delivery domain-conjugated A-SATE phosphotriester group is removed by intracellular thioesterase cleavage at the thioester bond. Based on the steric restrictions of the phosphate rules from above, we synthesized a chimeric passenger strand containing four A-SATE phosphotriesters that was duplexed to an RNN guide strand and conjugated to delivery domain peptides (DD-siRNN A4 ; Supplementary  Fig. 5a ). GFP DD-siRNN A4 conjugates self-delivered into cells to induce a dose-dependent GFP knockdown in the entire population in a noncytotoxic fashion, whereas nontargeting control DD-siRNN A4 conjugates failed to knock down GFP (Fig. 2e and Supplementary  Fig. 5b,c) . To ascertain the requirements for the number and location of A-SATE phosphotriesters, we synthesized a series of RNN oligonucleotides containing passenger and guide strand A-SATE (Supplementary Fig. 5a ). Regardless of position, delivery domain conjugation to two A-SATE phosphotriester siRNNs (DD-siRNN A2 ) induced an intermediate GFP RNAi response compared with DD-siRNNs containing three (DD-siRNN A3 ) or four (DD-siRNN A4 ) DD-conjugated A-SATE phosphotriester groups (Fig. 2f) . Self-delivered c-Myc DD-siRNNs efficiently induced a dose-dependent c-Myc RNAi response in a breast carcinoma cell line, whereas nontargeting control DD-siRNN conjugates did not (Fig. 2g and Supplementary Fig. 5a ). npg l e t t e r s Likewise, self-delivered Plk1 DD-siRNN conjugates containing hydroxyl O-SATE phosphotriesters induced a Plk1 RNAi response and appropriate G2 phase cell cycle arrest in a human osteosarcoma tumor cell line, whereas nontargeting control DD-siRNN conjugates did not (Fig. 2h and Supplementary Fig. 5a ).
We next tested the in vivo ability of siRNNs to induce RNAi responses versus wild-type siRNAs. To do so, we synthesized a hepatocyte-specific tris-N-acetylgalactosamine (GalNAc) targeting domain (Fig. 3a) that is currently being tested in RNAi clinical trials 34 . siRNNs targeting liver-specific ApoB contained a 5′ A-SATE (P#1) for conjugation to GalNAc plus nuclease stabilizing 5′ and 3′ terminal phosphorothioates (Fig. 3b and Supplementary Fig. 6 ). Control charged ApoB siRNAs contained a passenger strand with a single 5′ A-SATE phosphotriester (P#1) for conjugation to tris-GalNAc plus 2′ modifications matched to siRNNs and stabilizing 5′ and 3′ terminal phosphorothioates. In vivo, due to biophysical attributes of the target ApoB mRNA-including Ago2 accessibility and mRNA synthesis rates combined with the siRNA sequence used-a single subcutaneous 25 mg/kg dose into mice of both charged ApoB GalNAcsiRNAs and neutral ApoB GalNAc-siRNNs was required to induce significant ApoB RNAi responses at 72 h, although GalNAc-siRNNs induced a stronger RNAi response (Fig. 3c) . Charged siRNAs do not bind serum albumin (Fig. 3d) and are rapidly cleared by the kidneys (half-life <5 min) 35 , preventing effective intravenous administration. In contrast, we found that charge neutralized siRNNs avidly bound serum albumin (Fig. 3d) . A single intravenous 25 mg/kg dose of four variants of ApoB GalNAc-siRNNs into mice induced strong ApoB RNAi responses at 72 h, whereas a 25 mg/kg intravenous dose of GalNAc-siRNAs induced a poor RNAi response ( Fig. 3e and  Supplementary Fig. 6 ). GalNAc-siRNNs induced significant ApoB RNAi responses compared with GalNAc-siRNA treated animals (P < 0.05 to <0.01). GalNAc-siRNNs also induced a significant dose-dependent ApoB RNAi response (median effective dose, ED 50 ~10 mg/kg) compared with control GalNAc-siRNN-DMBs (P < 0.01 to <0.001) that contained six irreversible DMB phosphotriester groups on the guide strand (Fig. 3f) . Lastly, kinetic analyses of single intravenous dose of GalNAc-siRNN into ApoB-treated mice showed partial ApoB RNAi responses at 24 and 48 h, which reached a near maximum at 72 h and were maintained for >12 days (Fig. 3g ). These observations demonstrate for the first time the ability to synthesize and self-deliver phosphotriester siRNN conjugates that are intracellularly converted into charged phosphodiester siRNAs that induce robust RNAi responses in vivo.
RNAi responses induced by siRNA and microRNA (miRNA) have great potential for treating human disease, especially cancer and viral infections that hold a myriad of unique genetic targets 1-3 . However, due to their size and highly charged phosphodiester backbone, cellular delivery remains the main technological problem for development of systemic RNAi therapeutics. Because TRBP and Ago2 have strict chemical requirements for binding to charged, A-form doublestranded siRNAs 11, 12 , the siRNA phosphate backbone has-to the best of our knowledge-not previously been amendable to chemical manipulation. We addressed this problem by synthesizing RNAi prodrugs that contain neutral bioreversible phosphotriester groups that are intracellularly converted by thioesterases into charged phosphodiester siRNAs. Because siRNN oligonucleotide synthesis is modular, we synthesized RNN phosphoramidite building blocks that allow for the placement of phosphotriester groups at any location and chimeric combination on siRNNs. In the course of these studies, we synthesized >3,000 RNN oligonucleotides, demonstrating the robustness and versatility of our approach. We note that the phosphotriester chemistry can also be readily applied to miRNA mimetics as miRNN therapeutics. To further facilitate intracellular delivery, we also developed conjugatable A-SATE phosphotriester groups that allowed for siRNN conjugation to delivery and targeting domains. siRNNs have many drug-like properties such as high solubility and serum stability. They can be delivered systemically and produced with high synthetic yields using standard solid-phase oligonucleotide synthesis conditions. The collective attributes of siRNNs combined with distinct phosphotriester terminal groups and conjugation handles opens up entirely new avenues for molecularly sculpting the siRNN surface to optimize pharmacokinetics, cellular delivery and endosomal escape into a given tissue. We performed an in vivo siRNA to siRNN head-to-head comparison using the same ApoB sequence and modifications delivered by conjugation to the GalNAc targeting domain, and found that siRNNs were far superior to siRNAs (P < 0.001). Compared with other liver delivery approaches, such as lipid and synthetic nanoparticles that can achieve lower in vivo doses or cholesterol conjugations (which form large-micrometer particles in blood), GalNAc-siRNN conjugates have multiple positive attributes, including ease of synthesis, serum stability and a 5,000-fold smaller size that dramatically increases its diffusion coefficient compared with nanoparticle approaches. In summary, we believe siRNNs represent a technology that will open new avenues for RNAi therapeutics.
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